BIOMAT Database Logo BIOMAT Database Logo

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line? 2018

Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

UI MeSH Term Description Entries

Related Publications

Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
[Progression and future of CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer].
April 2021, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
January 2018, Therapeutic advances in medical oncology,
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment.
October 2023, Medicine,
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review.
January 2024, Breast cancer (Dove Medical Press),
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.
November 2021, Breast cancer research and treatment,
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
June 2019, Future medicinal chemistry,
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
October 2020, Breast cancer research and treatment,
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
October 2018, Asia-Pacific journal of clinical oncology,
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
October 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Clinton Yam, and Mien-Chie Hung, and Gabriel N Hortobagyi
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
June 2021, JCO clinical cancer informatics,
Copied contents to your clipboard!